Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival
Brieger KK, Peterson S, Lee AW, Mukherjee B, Bakulski KM, Alimujiang A, Anton-Culver H, Anglesio MS, Bandera EV, Berchuck A, Bowtell DDL, Chenevix-Trench G, Cho KR, Cramer DW, DeFazio A, Doherty JA, Fortner RT, Garsed DW, Gayther SA, Gentry-Maharaj A, Goode EL, Goodman MT, Harris HR, Høgdall E, Huntsman DG, Shen H, Jensen A, Johnatty SE, Jordan SJ, Kjaer SK, Kupryjanczyk J, Lambrechts D, McLean K, Menon U, Modugno F, Moysich K, Ness R, Ramus SJ, Richardson J, Risch H, Rossing MA, Trabert B, Wentzensen N, Ziogas A, Terry KL, Wu AH, Hanley GE, Pharoah P, Webb PM, Pike MC, Pearce CL, Consortium F. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology 2020, 158: 702-709. PMID: 32641237, PMCID: PMC7487048, DOI: 10.1016/j.ygyno.2020.06.481.Peer-Reviewed Original ResearchConceptsMenopausal hormone therapyOvarian cancer survivalMHT useResidual diseaseHormone therapyCancer survivalOvarian cancerHigh-grade serous carcinomaMacroscopic residual diseaseHormone therapy useFavorable prognostic factorPost-menopausal womenOvarian Cancer Association ConsortiumProportional hazards modelRecency of useImproved survivalPrognostic factorsTherapy useSerous carcinomaOvarian carcinomaHazards modelSmall studyAdvanced stageLarger studyLogistic regression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply